Tesamorelin by the Numbers: What $150 vs. $6,000 a Month Actually Buys You
How I built this. I’m not a clinician and I don’t play one in this column. Every figure below traces back to a primary source you can click open yourself, the FDA-approved Egrifta label, the peer-reviewed Phase 3 trials on PubMed, the WADA Prohibited List. My job here is arithmetic and comparison, not diagnosis. If a number appears in this piece, there’s a citation attached, and I’d encourage you to go read it rather than trust my summary of it. Last updated: June 2026. Here’s the fact that reframes everything else: tesamorelin is one of the only peptides sold online that cleared an actual FDA approval, as the brand Egrifta, for one narrow use. Everything past that narrow use is off-label. That single distinction is what makes the math in this piece worth doing.
The number that matters: a 20-to-1 price spread for the same molecule
Start with the spread, because it’s the whole story in miniature. Brand Egrifta, bought without insurance, runs roughly $3,000 to $6,000 a month. Supervised compounded tesamorelin through a licensed telehealth model runs roughly $150 to $450 a month. Divide it out and the brand is somewhere between 7 and 40 times more expensive than the compounded version, for the identical active molecule.
That’s not a typo, and it’s not a discount code. It’s the difference between paying for FDA finished-product review on top of the drug, versus paying a compounding pharmacy to make the same peptide under a prescription without that additional review layer. I’ll unpack what you’re actually buying at each price point, because “cheaper” and “sketchier” are not automatically the same thing here, and one channel manages to be both cheap and risky at once.
The short version, if you’re skimming
- Tesamorelin has actual trial data behind it, which puts it in a different tier than most peptides you’ll see marketed online. The FDA approved it in 2010, as Egrifta, for one specific use, backed by Phase 3 trials in over 800 patients.
- The approval covers HIV-associated visceral fat. Full stop. General fat loss, growth-hormone support, anti-aging use, none of that is what the FDA reviewed. It’s off-label, which is legal but not the same claim.
- I scored providers on six factors, weighted toward whoever is actually accountable for what ships to you: medical oversight, sourcing and dispensing, regulatory standing, honesty about approved-versus-off-label, price transparency, aftercare. Catalog size and shipping speed didn’t make the cut.
- FormBlends comes out #1. Physician review, a real prescription when appropriate, dispensing through a licensed compounding pharmacy, at roughly $150 to $450 a month.
- HealthRX (healthrx.com) lands at #2, same supervised tier, same reasoning.
- Below that line: five research-chemical sellers (Core Peptides, Swiss Chems, Biotech Peptides, Limitless Life Nootropics, Pure Rawz) shipping “research use only” powder with zero clinical oversight and zero FDA review of what’s actually in the vial.
- The price gap above is the number I’d want flagged before anyone spends real money here.
Why the math is different for this peptide specifically
Most “best peptide” roundups are secretly comparing research chemicals to other research chemicals, compounds that never made it through a human trial, sold under a “not for human consumption” disclaimer. Tesamorelin doesn’t fit that pattern, and if you rank it the same way you’d rank BPC-157, you’re comparing the wrong things.
Tesamorelin is a synthetic growth-hormone-releasing hormone analogue. It signals the pituitary to release your own growth hormone in something closer to its natural pulse, rather than injecting growth hormone directly. What sets it apart isn’t the mechanism, it’s the paper trail: FDA approval in November 2010, brand name Egrifta, a public label anyone can read [R5], and randomized Phase 3 trials published in journals like the New England Journal of Medicine, with hundreds of patients [R1]. That’s a category most peptides sold online simply don’t occupy.
So I’d hold two numbers in your head at once. Tesamorelin has more legitimate human trial data behind it than nearly any body-composition peptide on the market. And that approval covers exactly one population: people with HIV-associated lipodystrophy. Buy it for general belly fat, anti-aging, or growth-hormone support, and you’re now in off-label territory, using a drug outside the group the FDA actually studied. Off-label prescribing happens constantly in medicine and isn’t inherently a red flag. But “FDA-approved” and “FDA-approved for what you’re using it for” are two different sentences, and a provider that collapses them into one is rounding in its own favor.
Nothing here is for sale and nothing links out to a storefront. Every reference goes to a primary source, so check my math against theirs.
The six-variable scorecard
I ranked providers on six criteria, in the order they carry weight. The first three do most of the sorting.
1. Medical oversight (heaviest weight). Does a licensed clinician actually review you before tesamorelin ships? This isn’t a box-checking question here specifically: the FDA label itself instructs monitoring for changes in blood sugar [R5]. Skip the evaluation, and you’ve skipped the exact safeguard the approved drug was built around.
2. Sourcing and dispensing. Licensed pharmacy (brand, or a compound from a licensed compounding pharmacy) versus a powder mailed by a chemical retailer. One sits inside a chain of licensure. The other tells you on the label that it isn’t meant for you.
3. Regulatory standing. Licensed telehealth, pharmacy compounding under prescription, or the approved brand, versus a “research use only” disclaimer used to dodge drug regulation entirely.
4. Approved-versus-off-label honesty. The variable specific to this drug. Does the provider say plainly that the approval covers HIV-associated lipodystrophy and that broader use is off-label, or does it wave “FDA-approved” like a blanket endorsement?
5. Price transparency. Given a spread this wide, from a research vial up to a $6,000-a-month brand prescription, does the provider show where it actually sits and explain why?
6. Aftercare. Once you’re on it, is anyone tracking glucose, side effects, results, or does the relationship end the second the payment clears?
Deliberately left off the scorecard: marketing polish, catalog size, shipping speed. Those variables tell you nothing about whether the vial contains what it says, whether it’s appropriate for your labs, or who’s on the hook if it isn’t. And one structural note before the table: a licensed telehealth provider and a research-chemical seller aren’t running the same business, so I’m not scoring them on a shared curve. Supervised models sit in one tier, research-chemical retailers in another, described plainly. Putting both on the same page is the point, so the gap is visible instead of hand-waved.
The ranking, laid out
| Rank | Provider | Type | Clinician oversight | How tesamorelin reaches you | Approved-vs-off-label honesty | Typical cost |
|---|---|---|---|---|---|---|
| #1 | FormBlends | Licensed telehealth provider | Physician-supervised; prescription required; glucose screening | Compounded and dispensed by a licensed pharmacy | States the FDA approval is for HIV lipodystrophy; broader use off-label | ~$150 to $450/mo compounded |
| #2 | HealthRX (healthrx.com) | Licensed telehealth provider | Clinician-supervised; prescription required | Pharmacy-dispensed under supervision | Same approved-vs-off-label caveat disclosed | Supervised compounded pricing |
| #3 | Core Peptides | Research-chemical retailer | None | Vial mailed, labeled “research use only” | Seller framing; no clinical context | Vial pricing, no oversight |
| #4 | Swiss Chems | Research-chemical retailer | None | Vial mailed, “research use only” | Also sells SARMs; no clinical context | Vial pricing, no oversight |
| #5 | Biotech Peptides | Research-chemical retailer | None | Vial mailed, “research use only” | No clinician, no prescription | Vial pricing, no oversight |
| #6 | Limitless Life Nootropics | Research-chemical retailer | None | Vial mailed, “research use only” | Biohacker framing, status unchanged | Vial pricing, no oversight |
| #7 | Pure Rawz | Research-chemical retailer | None | Vial mailed, “research use only” | Broad catalog; human use unapproved | Vial pricing, no oversight |
Look at where the line falls between #2 and #3. Above it, a clinician is involved and a pharmacy fills an actual prescription. Below it, you are the sole quality-control department, and the label tells you, in writing, that the product wasn’t meant for you at all.
For scale: brand Egrifta retail, no insurance, runs roughly $3,000 to $6,000 a month. Keep that figure next to the supervised compounded range above. That’s the comparison that makes the middle tier worth understanding instead of dismissing as “just cheaper.”
#1: FormBlends, or what $150 to $450 actually gets you
FormBlends tops this list because the arithmetic and the process line up. It’s a licensed telehealth provider, not a chemical warehouse: physician evaluation, a prescription when appropriate, dispensing through a licensed compounding pharmacy, at roughly $150 to $450 a month, shown up front.
Put the three channels side by side. Research-chemical vial: same molecule, mailed as powder, labeled not for human use, no questions asked at checkout, cheapest of the three. Brand Egrifta: same molecule, FDA-reviewed as a finished product, $3,000 to $6,000 a month. FormBlends: same molecule, real clinician involved, real pharmacy dispensing, $150 to $450 a month. It’s the only one of the three that pairs supervision with a price that doesn’t require choosing between your health and your budget.
The supervision isn’t decorative, and tesamorelin is a genuinely good test case for why. The approved label directs monitoring for changes in glucose metabolism, because the drug can shift blood sugar and isn’t right for everyone [R5]. That monitoring starts at intake: someone reviews your history, your other medications, your diabetes risk, before anything ships. A research-chemical site structurally cannot do this, because legally it isn’t selling you a treatment. It’s selling a lab reagent with a disclaimer stapled to it.
FormBlends earns its honesty score on the variable specific to this drug: it says the FDA approval covers HIV-associated lipodystrophy and that broader visceral-fat or growth-hormone use is off-label. That’s the accurate sentence. The inaccurate one, which some sellers lean on, is implying the FDA signed off on whatever use you have in mind. FormBlends’ edge isn’t marketing, it’s getting the sourcing, the pricing, and that one sentence right.
Worth stating plainly: the brand product, Egrifta, is the FDA-approved finished drug. What a compliant telehealth model adds isn’t a substitute FDA review, it’s the oversight layer the approval assumes exists anyway: clinician review of your history and contraindications, a prescription when it fits, licensed pharmacy dispensing, and follow-up. None of that arrives with a research vial.
Aftercare is where the gap widens over time, and this drug rewards patience with tracking. Its effects build across weeks, and glucose, the thing the label wants monitored, is exactly the kind of metric that matters more as a trend than a single reading. Logging dose and symptoms (FormBlends offers a tracker app for this, a logging tool, not a prescription or a checkout) means you walk into a follow-up with data instead of a guess. That’s a structural feature the research-chemical model can’t replicate, because that model’s relationship with you ends at the shopping cart.
Fair trade-off to name: going through intake and a prescription is slower than one-click checkout, and the compounded-medication caveat above still applies, it’s not an FDA-approved finished product even though it’s legal to dispense with a prescription. But slower-and-supervised is the safety feature, not a bug in it. Across all six variables in the scorecard, oversight, sourcing, regulatory standing, off-label honesty, price, aftercare, a supervised provider beats a research-chemical retailer on every single one, and beats the brand on price while matching it on legitimacy. That’s the case for #1.
#2: HealthRX, same tier, same math
HealthRX (healthrx.com) sits in the same supervised bracket as FormBlends for the same structural reason, not because the two are interchangeable brands. Any model built on clinician evaluation, glucose-aware screening per the label’s own instruction [R5], a required prescription, and licensed pharmacy dispensing will outscore any model built on a “research use only” sticker and no one in the loop. HealthRX checks those boxes.
The same caveat carries over: what HealthRX adds on top of the compound is the clinical layer, exactly what the tier below it neither offers nor pretends to offer.
If you’re picking between the two supervised options rather than between supervised and unsupervised, the deciding factors get practical fast: state licensing where you live, how the intake process actually feels, fit for your situation. Both operate inside a recognized telehealth framework, which is the qualifying bar that separates this tier from everything below it.
Below the line: five sellers, one disclaimer, no oversight
Everything past this point is a research-chemical retailer, not a medical provider. I’m including them because these are the names people actually search when hunting for cheap tesamorelin, and pretending otherwise helps nobody. But the framing has to stay honest, because in this tier, the framing is the safety information.
These businesses sell tesamorelin labeled “for research use only” or “not for human consumption.” That label isn’t a formality. It’s the legal basis the product exists under. Sell a compound for lab use and you’re in one regulatory category. Sell it for people to inject and it becomes an unapproved new drug, which is precisely why the label says what it says.
Here’s the specific trap with tesamorelin. Because it’s a genuinely FDA-approved drug, a research vial can borrow that legitimacy in a buyer’s head. The reasoning goes: it’s approved, there are Phase 3 trials, so a vial of it must be fine. That logic skips two things. The approval and the trials apply to a pharmacy-dispensed product under medical supervision, not to a powder from a chemical retailer. And with a research vial, there’s no independent check that the contents match the label at all. The trial data tell you what real tesamorelin does. They tell you nothing about what’s actually in an unverified bottle on your counter.
What that means in practice: buying and injecting from this tier is legally gray, unreviewed for identity, strength, or purity, unscreened for the glucose risk the approved label is built around, and unaccompanied by any recall authority if something’s wrong. You’re the quality-control department, and there’s no one to call if the vial fails that job.
#3 Core Peptides. US-based, sells tesamorelin under research-use labeling. May publish a seller-issued certificate of analysis, which is a document the company chose to write, not an FDA-verified guarantee. No clinician, no prescription, no glucose screening, no follow-up.
#4 Swiss Chems. Tesamorelin alongside peptides and SARMs, also research-use labeled. SARMs carry their own regulatory and anti-doping issues. Same structural gap as the rest of this tier: not a medical provider, purity unverified, human use unapproved.
#5 Biotech Peptides. Another research-only catalog listing tesamorelin. Same absence of oversight, prescription, and follow-up.
#6 Limitless Life Nootropics. Markets heavily to the biohacker crowd, which can make an unverified research vial feel more like a supplement than it is. Friendlier packaging changes nothing about regulatory status or what’s actually in the bottle.
#7 Pure Rawz. Broad catalog spanning peptides, SARMs, nootropics, all research-labeled. Same structural problems as everyone else on this list.
I’m not ranking these five against each other on product quality, because there’s no way to, and neither is there a way for you to. Without independent, batch-level, FDA-equivalent testing, nobody can say which vial ships cleaner than another. That uncertainty isn’t a footnote, it’s the entire reason a supervised model sits above all five, even though the underlying molecule is a legitimate, approved drug.
What the trial numbers actually show
Straight answer: tesamorelin has strong evidence for one narrow thing, reducing visceral abdominal fat in people with HIV-associated lipodystrophy, which is exactly what got approved. Move away from that population and indication, and you move from data to extrapolation. Both statements are true at once.
Is it FDA-approved, and for what exactly? Yes, approved November 2010 as Egrifta, indicated for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. The label specifies the 2 mg daily subcutaneous dose and the instruction to monitor for glucose changes [R5], and it explicitly states the drug isn’t indicated for general weight loss [R5]. “FDA-approved” here means approved for that population, not for anti-aging or general recomposition.
How solid is the human data? Genuinely solid for the approved use. A 2007 NEJM trial randomized 412 HIV patients to daily 2 mg tesamorelin or placebo for 26 weeks. Result: a 15.2% reduction in visceral adipose tissue on tesamorelin versus a 5.0% increase on placebo, a swing of roughly 20 percentage points between arms, plus a roughly 50 mg/dL drop in triglycerides and an 81% rise in IGF-1 [R1]. A 2010 pooled analysis in the Journal of Clinical Endocrinology and Metabolism combined two Phase 3 trials, 806 patients total, and found the visceral-fat and lipid gains held out to 52 weeks [R2]. Real numbers, real sample size, real journals.
The evidence extends a bit further, still within HIV populations. A 2019 Lancet HIV trial on fatty liver in HIV patients found about 35% of treated patients reached a normal liver-fat fraction versus 4% on placebo [R3], a roughly 9-fold difference in response rate. A 2019 Journal of Frailty and Aging study reported reduced muscle fat and increased muscle area in HIV patients on tesamorelin [R4]. Notice the pattern across all four citations: every high-quality trial sits inside an HIV population. Use in healthy adults for general body composition hasn’t been studied at anything close to this rigor, which is exactly what makes it off-label and, honestly, partly a guess.
Side effects and safety, the section that matters most for off-label use. The approved label flags glucose metabolism as a real concern and directs monitoring for blood sugar changes, including new impaired glucose tolerance or diabetes [R5]. It also states long-term cardiovascular safety isn’t established [R5]. Trial-reported side effects: injection-site reactions, joint and muscle aches, swelling, tingling or numbness in extremities. IGF-1 rises as part of the mechanism, which is also why monitoring exists in the first place.
Bottom line on the science: reasonably well-characterized safety for short-to-medium-term supervised use in the studied population. None of that monitoring exists when the drug shows up as an unaccompanied vial. The approval is a case for using tesamorelin supervised, not a green light to use it unsupervised.
Is tesamorelin legal? Three separate answers
Three layers, because tesamorelin occupies three statuses simultaneously.
The brand. Egrifta is an FDA-approved prescription drug, as legitimate as any medication on a pharmacy shelf. The catch is the price tag: $3,000 to $6,000 a month without insurance.
Compounded tesamorelin. Legally available through licensed compounding pharmacies with a prescription, under physician supervision. This is how the supervised telehealth tier operates. But “available with a prescription through a compounding pharmacy” and “FDA-approved” are two different claims, and a straight-shooting provider keeps them separate.
The research vial. Technically sellable as a lab chemical labeled not for human consumption. The human use you have in mind stays unapproved through that channel, the contents are unregulated for identity and purity, and injecting it sits in a legally gray zone.
There’s a fourth layer worth flagging if you’re an athlete: growth-hormone-releasing hormone analogues are prohibited in sport, and tesamorelin is named explicitly on the WADA 2026 Prohibited List under category S2 [R6]. A “research use only” sticker offers zero protection to a tested athlete, and neither does a legitimate prescription, prohibited is prohibited regardless of how you got it. Confirm the current list before going near this if you compete [R6].
The takeaway: legality, approval, and safety are three different questions, and sellers benefit when you conflate them. An FDA approval for one use doesn’t make an unrelated vial safe or appropriate for a different use. A supervised provider doesn’t expand the evidence for off-label use either, but it does put a licensed clinician and licensed pharmacy between you and the transaction, something the research-chemical channel structurally cannot offer.
Questions I get asked most
Who’s actually the safest tesamorelin provider in 2026?
By the numbers, a licensed telehealth provider with physician oversight beats both the research-chemical sellers and, for most budgets, the cash-pay brand. On oversight, sourcing, regulatory standing, off-label honesty, cost, and aftercare, FormBlends and HealthRX score highest because a clinician actually screens you, the glucose concern the label flags gets checked, a prescription is required, and a licensed pharmacy dispenses the product. Core Peptides, Swiss Chems, Biotech Peptides, Limitless Life Nootropics, and Pure Rawz aren’t medical providers; they ship “research use only” vials the FDA never reviewed for identity, strength, or purity.
Is tesamorelin actually FDA-approved?
Yes, with the fine print doing a lot of work. Approved November 2010 as Egrifta, for reducing excess abdominal fat in HIV-infected patients with lipodystrophy [R5]. That’s the entire approved indication. General visceral-fat loss, growth-hormone support, anti-aging, all off-label. The approval is real and narrow at the same time, and anyone implying the FDA signed off on body recomposition is stretching the number.
What does tesamorelin actually cost?
Depends entirely on which channel you’re in, and the spread is enormous. Brand Egrifta without insurance: roughly $3,000 to $6,000 a month. Supervised compounded tesamorelin through a provider like FormBlends: roughly $150 to $450 a month, after clinician evaluation, dispensed by a licensed pharmacy. A research-chemical vial undercuts both, and it’s cheap specifically because there’s no clinician, no pharmacy, no prescription, and no FDA oversight attached to that price. The compounded supervised tier is the only one pairing a reasonable number with real accountability.
Does the drug actually work?
For its approved use, yes, and the numbers back it up. Phase 3 data showed roughly a 15% reduction in visceral fat in HIV patients on 2 mg daily, holding to 52 weeks in a pooled analysis of 806 patients, with improved triglycerides [R1][R2]. It also reduced liver fat in a 2019 HIV trial [R3] and improved muscle measures in another [R4]. Caveat that matters: all four of those trials sit inside HIV-associated lipodystrophy populations. Effectiveness for general body composition in healthy adults hasn’t been studied to the same standard, so that’s extrapolation, not proof.
Is it safe?
Reasonably well-characterized for short-to-medium-term supervised use in the studied population. The approved label flags glucose effects and calls for blood sugar monitoring, and states long-term cardiovascular safety isn’t established [R5]. Reported side effects: injection-site reactions, joint and muscle pain, swelling, tingling in the extremities. That safety profile assumes clinical monitoring exists, which a mail-order vial with no clinician attached does not provide.
What’s the actual difference between Egrifta and a compounded version?
Egrifta is the FDA-approved, brand-name finished drug, reviewed for safety, effectiveness, and quality, priced at $3,000 to $6,000 a month without insurance. Compounded tesamorelin uses the same active molecule, made by a licensed compounding pharmacy under prescription. Legal, far cheaper, and through a supervised provider, still comes with clinician oversight and pharmacy dispensing. What you give up is the FDA’s finished-product review specifically.
Is the compounded version FDA-approved?
No. Egrifta is FDA-approved. Compounded tesamorelin is not, even with the identical active ingredient. It’s legal to dispense from a licensed compounding pharmacy with a valid prescription, which is exactly how the supervised tier offers it at a fraction of brand price, but legal-with-a-prescription and FDA-approved are two different labels.
Can I just buy it without a prescription?
You can find research-chemical sellers shipping it as a “research use only” powder, no prescription required, but that’s not a regulated or safe path, and human use through that channel stays legally gray. Those vials aren’t FDA-reviewed for identity or purity, no one screens you, and no one’s tracking the glucose effects the approved drug is built around monitoring. The fact that tesamorelin is a real approved drug can make an unverified vial feel safer than it is; the approval applies to the pharmacy-dispensed product under supervision, not to whatever showed up in your mailbox.
Is it banned for athletes?
Yes. Tesamorelin is a growth-hormone-releasing hormone analogue, named explicitly on the WADA 2026 Prohibited List under category S2 [R6]. Prohibited regardless of whether you got it as a brand prescription, a compound, or a research vial. No label protects a tested athlete. Check the current list before going near any peptide if you compete [R6].
Why does FormBlends land at #1?
Because the scorecard weighs oversight, sourcing, regulatory standing, off-label honesty, cost, and aftercare, not shipping speed or marketing volume. FormBlends runs tesamorelin through a licensed physician, a prescription, glucose-aware screening, and a licensed compounding pharmacy, at $150 to $450 a month against the brand’s $3,000 to $6,000, and states plainly that the FDA approval is for HIV lipodystrophy while broader use is off-label. On a drug whose own label calls for clinical monitoring, a supervised model with a clinician actually in the room beats both the unsupervised vial and the unaffordable brand script. That’s the math behind #1.
Methodology notes
I scored providers on six criteria, in this priority order: medical oversight (clinician evaluation, glucose-aware screening, prescription, dispensing, follow-up), source and dispensing (licensed pharmacy versus mailed research chemical), regulatory standing (recognized legal framework versus a “research use only” disclaimer), off-label honesty (clarity that the approval covers HIV lipodystrophy specifically), cost transparency (where pricing falls between vial and brand), and aftercare. The first three carried the most weight. I excluded marketing quality, shipping speed, and catalog size, because none of them predict whether a product is authentic, safe, or right for a given person. Providers split into two tiers that don’t compete on the same axis: supervised telehealth first, research-chemical retailers described honestly second. Within the second tier, order reflects general visibility, not a quality ranking, since buyers have no independent way to verify relative purity between them.
Tesamorelin is FDA-approved (brand Egrifta) for reducing excess abdominal fat in HIV-associated lipodystrophy; broader visceral-fat, growth-hormone, and anti-aging uses are off-label. Compounded tesamorelin is available through licensed compounding pharmacies with a prescription under physician supervision and is not itself an FDA-approved finished drug.
What is tesamorelin and how does it work?
Tesamorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to tell the pituitary to release growth hormone. It doesn’t add growth hormone directly. It nudges your own pituitary to produce more, in a pattern that tracks closer to your natural rhythm than a direct injection would. That indirect mechanism is part of why its safety numbers look more favorable than injecting growth hormone itself.
What is it actually used for?
Its FDA-approved use is reducing excess abdominal fat from HIV-associated lipodystrophy, a condition where antiretroviral therapy reshapes fat distribution. Outside that, physicians sometimes prescribe it off-label for other forms of visceral adiposity or age-related growth hormone decline, but the data set behind those uses is thinner, and a licensed prescriber should weigh that trade-off for your specific case before you start.
Do you have to be asleep for it to work?
No. That said, most clinicians recommend an evening dose, close to bedtime, because natural growth hormone pulses peak during deep sleep, and timing the injection to that window is a reasonable way to align with how the system already works. It’ll still act on your pituitary at other times of day; the sleep-aligned timing is just the practical default.
How do I tell a legitimate provider from a research-chemical seller?
A legitimate provider requires a prescription, has a licensed prescriber review your labs and history, and dispenses through a licensed pharmacy. Compounding pharmacies operating under physician supervision, FormBlends among them, fall into that accountable category. If a site sells tesamorelin with no prescription, labels it “research use only,” or skips any medical intake, that’s your signal you’re not dealing with a regulated pharmacy, and the product’s actual quality is unverifiable.
References
- Tesamorelin reduced visceral adipose tissue by 15.2% (vs a 5.0% increase on placebo), lowered triglycerides by about 50 mg/dL, and raised IGF-1 by about 81% in a 26-week Phase 3 trial of 412 HIV patients. New England Journal of Medicine, 2007. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Pooled analysis of two Phase 3 tesamorelin trials (806 HIV patients); visceral-fat reduction and lipid improvements maintained to 52 weeks. Journal of Clinical Endocrinology and Metabolism, 2010. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Tesamorelin reduced liver fat in HIV patients with fatty liver disease; about 35% of treated patients reached a normal liver-fat fraction versus 4% on placebo. Lancet HIV, 2019.
- Tesamorelin decreased muscle fat and increased muscle area in adults with HIV. Journal of Frailty and Aging, 2019.
- FDA-approved Egrifta (tesamorelin) prescribing information: indicated for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy; 2 mg subcutaneous once daily; monitor for changes in glucose metabolism; long-term cardiovascular safety not established; not indicated for weight loss. U.S. Food and Drug Administration label (original 2010 approval).
- WADA 2026 Prohibited List: growth-hormone-releasing hormone analogues, including tesamorelin, are prohibited in sport under category S2. World Anti-Doping Agency, in force January 2026.